ArticleLipids in health and disease2025
Liver fat mediates hippocampal-orbitofrontal reward circuit disruption and cognitive-emotional impairments in MASLD.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk.Lipids in health and disease · 2026Review
- Correction: Liver fat mediates hippocampal-orbitofrontal reward circuit disruption and cognitive-emotional impairments in MASLD.Lipids in health and disease · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundAs a major chronic liver condition, metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to numerous extrahepatic manifestations, including cognitive and emotional dysfunction. However, its neuroanatomical and functional brain correlates remain unclear. This study investigates cerebral alterations in MASLD by examining structural differences via voxel-based morphometry (VBM), along with functional features using resting-state functional connectivity (FC). METHODS AND PATIENTS: Seventy-four MASLD patients and sixty-two demographically matched healthy controls (HC) underwent structural MRI and resting-state fMRI. Group differences in gray matter volume (GMV) and FC were analyzed using VBM and seed-based FC methods. Correlations and mediation analyses were further used to assess the relationships among abnormal GMV, altered resting-state FC and clinical indicators in MASLD individuals.
resultsPatients with MASLD exhibited reduced GMV in the bilateral hippocampus, left parahippocampal gyrus, left middle temporal gyrus, right fusiform gyrus, right supplementary motor area (SMA), and right cerebellum. Importantly, liver fat content fully mediated the effects of hippocampal atrophy on cognitive-emotional symptoms. Seed-based FC analysis further revealed decreased connectivity between the right hippocampus and the right orbitofrontal cortex. This reduction in connectivity was also associated with worse cognitive function and a higher waist-to-hip ratio.
conclusionMASLD-related brain atrophy and functional disruption are linked to visceral adiposity and neuropsychiatric deficits. The mediating role of liver fat highlights the importance of dual-pathway interventions that target both metabolic health and neural protection, potentially reducing long-term neurocognitive disability burdens and enabling accessible risk stratification in practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.